Member Info for B2HS2L

Hi EXMEX -
Have emailed Mandy with the issue, so I hope to get what the company thinks should be on the RNS soon, -

Novacyt SA or Novacyt UK Holdings.

+++

On another matter, do you have any information on the pre-christmas rumour that Novacyt might be interested in YouSeq?

UPshunt -

From that link:

"Reports abound that one measure at least looks set to ease: that of demanding all travellers, regardless of vaccination status, must present a negative coronavirus test (PCR or lateral flow) before being allowed to embark on their journey to the UK."

We know that the amount of Omicron infection is set to increase from here on.

Airline cabin staff will being going sick in numbers large enough to cancel many flights to UK.

Some airlines might have to cancel UK flights in order to satisfy cabin staff unions in safeguarding staff health.

This hasn't been thought through has it?

EXMEX -

From the RNS "The Liquidity Agreement is governed by French law"

That IMO is why the agreement was signed between Novacyt S.A. France and Invest Securities SA.

I think you are thinking of Novacyt S A UK which has been disolved in favour of Novacyt UK Holdings.

Blue83 -
"Perhaps Mullis heard what was coming."

I think there were whispers yesterday about what was coming, hence the selling.

https://indianexpress.com/article/india/manufacturers-question-icmrs-5-day-window-to-license-its-omicron-kit-7704870/

!
"While government agencies procure standard RT-PCR kits for Rs 20-30 each, a SGTF-based Thermo Fisher kit costs them at least Rs 240."
Unsure what journalistic standards indianexpress.com adhere to, - may be kosher, may not.

Suggest you look yourself up HereKittyKitty.
That facility is upfucced.

Uggy - No they are operating via stealth.
There must be some sp affecting news they are bound to make public, but we aren't being advised.
Recall the directors are probably not able to invest because of what they know about the DHSC dispute, and contractually bound not to advise others.

My view is they are using the dispute to stop other companies bidding, allowing the work required to achieve mid-cap status to accrue, such that when information released, sp will rise creating shareholder value, - BUT NOT before the BoD have acquired more shares.

Considerably less grunting here, such that we can concentrate on some fine research of late,
- you know who you are - well done.

Thanks for the links Ad4you :o)

troublesome -
ie
No time to rearrange personal holding when the board provide the news, - good and bad - that they are currently withholding.

viz
1 Possible white label instrument manufacture
2 Personnel changes at senior management level.

Apologies if posted before:

https://www.medlabme.com/en/visit/exhibitor-list.html

Novacyt on the exhibitor list for Medlab Middle East 2022 - 24/27.01.2022

Our sales in middle east could do with some support.

++++

It would seem that certain posters are making this board hard work, - don't engage would be my advice.

We've got our work cut out to find the smallest pieces of info because our management mistreat PI's by not divulging information that is sp sensitive.
They are not the only board doing this, but it does mean we need to be extra vigilant else we are left without a chair when the music stops.

"Lastly, covid has allowed us to build an excellent foundation into the diagnostic industry. This can and will be used when the time comes to switch into Sepsis, cancer, C diff, HIV, DNA and whatever else is of interest to us."
++++

Doesn't look like we will be on schedule with the aspergillus fungus launch:

From RNS 24 February 2021:

"Development of a new test panel to detect aspergillosis fungal infections
Aspergillosis is an infection caused by aspergillus fungus common in immune compromised patients4, and more recently has been associated with co-infection in patients with SARS-CoV-25 infections and COVID-19-associated pulmonary aspergillosis6. The infection is associated with long-term ventilation of patients. Outside of SARS-CoV-2 infections, aspergillosis also remains a potentially serious respiratory infection, affecting ~5 million patients worldwide7.

Novacyt's new multiplex PCR assay panel will detect all five major aspergillus sub-types and will run on the Company's q32 instruments, as well as open platforms. Novacyt expects to begin validation studies soon, with the potential to launch during H2 2021.

Once launched, the new assay panel will be the second product in the Company's COVID-19+ portfolio, following the launch of the Winterplex™ multiplex assay panel in August 2020. This launch is also in line with Novacyt's strategy to expand its portfolio of clinical use, respiratory diagnostic products."

Reposted from 20.12.2021:

https://www.gov.uk/government/publications/nhs-test-and-trace-how-we-test-your-samples/nhs-test-and-trace-how-we-test-your-samples

"Partner laboratories
A partner laboratory provides a high volume of testing for NHS Test and Trace alongside its usual activities.

These laboratories are different to Lighthouse laboratories. The laboratories can be acquired through partnership agreements with the public, private and academic sectors and can contribute tens of thousands of tests to the overall testing capacity."

+++

I'm assuming Novacyt has no spare labs to turn turn over to 'partner labs',
as the speed of R&D development precludes this.
We don't need the money, - we should continue R&D at best speed.

Anyway - the way things are going, NHS Test and Trace are going to need partner labs for many months ahead, - that is simply not feasible for NCYT which will in 2022 put the labs to better use developing new products.

++++

Talking of new products, are we aware of SNP-sig product codes
SNPsig® SARS-CoV-2 (VUI-21MAR-02) PRODUCT CODE R00151 - P3 - Phillipines Variant
SNPsig® SARS-CoV-2 (B.1.1.529) PRODUCT CODE R00148 - (B.1.1.519) Mexico Variant

as per sales flyer - https://genesig.com/assets/files/mm119_issue_9_snpsig_range.pdf

apologies -
Sincerely hope COVID-HT Direct takes no where near 1hr 20min following RNA extraction & set up in a high throughput lab.

DRB -
"So in direct competition with our Genesig HT test." - 10:21 post

"The (Clarigene) assay has a turnaround time of 1hr 20min following RNA extraction & set up" - 09:09 post

From RNS 24.02.2021 -
"Launch of CE Mark COVID-HT Direct
Novacyt announces the launch of its next generation high-throughput PCR test for COVID-19 (COVID-HT Direct), which has been CE Mark approved. This follows the launch of the Company's first high-throughput PCR test for COVID-19 (COVID-HT) in June 2020. The new test eliminates the need for automated extraction systems in a high-volume PCR laboratory, reducing processing time, cost and labour of testing by up to 30%. COVID-HT Direct is already in use at one of the UK's Lighthouse laboratories and is being validated for use with private high-throughput PCR laboratory partners."

Also from 09:09 post
"On 30th June 2020, Yourgene revealed the launch of its Clarigene™ SARS-CoV-2 test for research use
only (RUO). The test was initially made available to Yourgene's customers as evaluation kits, with a
CE marked in vitro diagnostic kit for diagnostic use released at the start of August following the
receipt of the CE-IVD mark"

++++
Clarigene may be a competitor for COVID-HT, but not COVID-HT Direct, which has a 6 months head start on Clarigene in terms of fulfilling customer need for high throughput laboratories.

Sincerely hope COVID-HT Direct takes no where near 1hr 20min following RNA extraction & set up in a high lab.

That job spec EXMEX, I'll see if it cross checks on a few other agencies, if not too late.
Interesting that discuss Canada also.

+++++++++++++++++++++++++++++

I was wondering if a Partner laboratory, - one that "provides a high volume of testing for NHS Test and Trace alongside its usual activities", might also be the sort of laboratories that could use COVID-HT Direct.

RNS - Research and Development Update - 24.02.2021
"COVID-HT Direct is already in use at one of the UK's Lighthouse laboratories and is being validated for use with private high-throughput PCR laboratory partners."
They mean Cambridge, but the high throughput partners who may also by now be the partner labs are the interest here.

Updated 08.12.2021 - Guidance
NHS Test and Trace: how we test your samples

https://www.gov.uk/government/publications/nhs-test-and-trace-how-we-test-your-samples/nhs-test-and-trace-how-we-test-your-samples

"Partner laboratories
A partner laboratory provides a high volume of testing for NHS Test and Trace alongside its usual activities.

These laboratories are different to Lighthouse laboratories. The laboratories can be acquired through partnership agreements with the public, private and academic sectors and can contribute tens of thousands of tests to the overall testing capacity."

"Automation and technology
As well as building a vast new laboratory network, NHS Test and Trace has invested in new innovative testing technology which means we can operate faster and with increased capacity and develop a flexible pandemic response infrastructure that can respond to surges in demand.

This includes LGC’s EndPoint PCR (EPCR) testing workflow for COVID-19, which has ultra-high capacity and is used in our 2 largest laboratories, Royal Leamington Spa and Milton Keynes.

In addition, new technology to rapidly detect COVID-19 mutations indicating whether positive test samples contain known variants is being rolled out by the government in NHS Test and Trace laboratories.

The technology – known as ‘genotype assay testing’ – is set to halve the time it currently takes to identify if a positive COVID-19 sample contains a mutation indicative of a known variant of concern, and will be used in addition to standard testing for COVID-19 to identify cases quickly.

Genotype assays complement existing surveillance work that uses genomic sequencing to look for variants in COVID-positive samples. Genomic sequencing surveillance will continue to detect new variants and mutations.

Where new variants or mutations are identified, the technology can be adapted to test for them as well, meaning the technology can be easily deployed to track the variants of most concern."

Hope this helps Saint:
PathFlow® COVID-19 Rapid Antigen Pro has been available since June 2021, - professional use only
PathFlow® COVID-19 Rapid Antigen has not been launched yet.

Ohhh errr - THIS is the link I meant to post -
https://twitter.com/DavidBurton1971/status/1472879110091325441

https://twitter.com/blad3sharp/status/1331020149936238596